Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine
- PMID: 12438235
Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine
Abstract
Epigenetic modifications of cytosine residues in DNA and the amino termini of histone proteins have emerged as key mechanisms in chromatin remodeling, impacting both the transcriptional regulation and the establishment of chromosomal domains. Using the chromatin immunoprecipitation (ChIP) assay, we demonstrate that aberrantly silenced genes in cancer cells exhibit a heterochromatic structure that is characterized by histone H3 lysine 9 (H3-K9) hypermethylation and histone H3 lysine 4 (H3-K4) hypomethylation. This aberrant heterochromatin is incompatible with transcriptional initiation but does not inhibit elongation by RNA polymerase II. H3-K9 methylation may, therefore, play a role in the silencing of tumor-suppressor genes in cancer. Treatment with 5-aza-2'-deoxycytidine (5-Aza-CdR), previously known for its ability to inhibit cytosine methylation, induced a rapid and substantial remodeling of the heterochromatic domains of the p14ARF/p16INK4a locus in T24 bladder cancer cells, reducing levels of dimethylated H3-K9 and increasing levels of dimethylated H3-K4 at this locus. In addition, 5-Aza-CdR increased acetylation and H3-K4 methylation at the unmethylated p14 promoter, suggesting it can induce chromatin remodeling independently of its effects on cytosine methylation.
Similar articles
-
Histone methylation is a critical regulator of the abnormal expression of POU5F1 and RASSF1A in testis cancer cell lines.Int J Androl. 2011 Apr;34(2):110-23. doi: 10.1111/j.1365-2605.2010.01063.x. Int J Androl. 2011. PMID: 20497257
-
Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells.Oncol Rep. 2009 Nov;22(5):1221-7. doi: 10.3892/or_00000558. Oncol Rep. 2009. PMID: 19787243
-
Re-expression of methylation-induced tumor suppressor gene silencing is associated with the state of histone modification in gastric cancer cell lines.World J Gastroenterol. 2007 Dec 14;13(46):6166-71. doi: 10.3748/wjg.v13.i46.6166. World J Gastroenterol. 2007. PMID: 18069755 Free PMC article.
-
[The roles of histone lysine methylation in epigenetic regulation].Yi Chuan. 2007 Apr;29(4):387-92. doi: 10.1360/yc-007-0387. Yi Chuan. 2007. PMID: 17548299 Review. Chinese.
-
DNA methylation and gene silencing in cancer.Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S4-11. doi: 10.1038/ncponc0354. Nat Clin Pract Oncol. 2005. PMID: 16341240 Review.
Cited by
-
MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes.Cell Death Dis. 2023 Oct 18;14(10):686. doi: 10.1038/s41419-023-06197-x. Cell Death Dis. 2023. PMID: 37852977 Free PMC article.
-
DNA methylation cooperates with H3K9me2 at HCN4 promoter to regulate the differentiation of bone marrow mesenchymal stem cells into pacemaker-like cells.PLoS One. 2023 Aug 29;18(8):e0289510. doi: 10.1371/journal.pone.0289510. eCollection 2023. PLoS One. 2023. PMID: 37643180 Free PMC article.
-
Epigenetic regulation of pulmonary inflammation.Semin Cell Dev Biol. 2024 Feb 15;154(Pt C):346-354. doi: 10.1016/j.semcdb.2023.05.003. Epub 2023 May 23. Semin Cell Dev Biol. 2024. PMID: 37230854 Review.
-
Epigenetic regulation of chemokine (CC-motif) ligand 2 in inflammatory diseases.Cell Prolif. 2023 Jul;56(7):e13428. doi: 10.1111/cpr.13428. Epub 2023 Mar 5. Cell Prolif. 2023. PMID: 36872292 Free PMC article. Review.
-
Modulating epigenetic modifications for cancer therapy (Review).Oncol Rep. 2023 Mar;49(3):59. doi: 10.3892/or.2023.8496. Epub 2023 Feb 17. Oncol Rep. 2023. PMID: 36799181 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Research Materials